FY2026 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at Leerink Partnrs reduced their FY2026 EPS estimates for shares of IQVIA in a research report issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $12.46 per share for the year, down from their previous estimate of $12.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2027 earnings at $13.78 EPS.

A number of other brokerages have also recently commented on IQV. JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. Evercore ISI reduced their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Up 1.6 %

NYSE IQV opened at $194.38 on Thursday. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a 50-day simple moving average of $224.22 and a 200 day simple moving average of $227.56. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $35.28 billion, a PE ratio of 25.51, a P/E/G ratio of 1.97 and a beta of 1.51.

Institutional Investors Weigh In On IQVIA

Several large investors have recently made changes to their positions in the stock. FMR LLC lifted its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA in the 3rd quarter valued at about $147,683,000. 1832 Asset Management L.P. grew its holdings in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter worth approximately $70,610,000. Finally, Impax Asset Management Group plc lifted its position in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.